Chemomab Therapeutics Ltd. (CMMB)

USD 1.59

(-3.64%)

Market Cap (In USD)

29.98 Million

Revenue (In USD)

-

Net Income (In USD)

-24.22 Million

Avg. Volume

249.19 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.45-2.55
PE
-
EPS
-
Beta Value
0.303
ISIN
US16385C1045
CUSIP
03280X102
CIK
1534248
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Adi Mor George Ph.D.
Employee Count
-
Website
https://www.chemomab.com
Ipo Date
2019-02-12
Details
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.